Aoxing Pharmaceutical Company, Inc. announced that its Chinese subsidiary has received from the State Food and Drug Administration of China a license to produce the active pharmaceutical ingredient in Pholcodine. The company has commenced preparation for the government's Good Manufacturing Practices inspection, which is the last regulatory hurdle before the company can take the product to market in China.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0042 USD | +5.00% |
|
+5.00% | +35.48% |
1st Jan change | Capi. | |
---|---|---|
+35.48% | 1.43M | |
+20.03% | 43.46B | |
+24.71% | 22.61B | |
+16.89% | 15.15B | |
+23.72% | 14.83B | |
+57.73% | 13.08B | |
-0.05% | 6.79B | |
-12.34% | 6.72B | |
-8.87% | 5.73B | |
+12.71% | 5.45B |
- Stock Market
- Equities
- AOXG Stock
- News Aoxing Pharmaceutical Company, Inc.
- Aoxing Pharmaceutical Company, Inc. Announces Receipt of Production License for Pholcodine